Figure 8.

DXM released from NLCs counteracts induction of CD86 by LPS. NPC cultures were treated with soluble DXM, empty NLCs and DXM-loaded NLCs at three different concentrations (5, 10 and 50 µg/mL). LPS (100 ng/mL) was applied 45 min later. On the next day, NPC populations were phenotypically characterized: LSECs (CD45⁺ CD32b⁺), KCs (CD45⁺ F4/80⁺) and DCs (CD45⁺ CD11c⁺). The activation state of each cell type was studied by CD86 marker assessment. The gating strategy has been described [39]. Data represents the mean ± SEM obtained in 3 independent experiments. Significantly different from positive control (LPS only): no significant difference (ns); * p < 0.05; ** p < 0.01; **** p < 0.0001 (one-way ANOVA, Dunnett’s multiple comparisons test).